Advancing Science. Improving Connections.

Next-generation transdermal cannabinoid therapeutics to improve the lives of patients affected by rare and near-rare neuropsychiatric conditions.

Our Patients

Focusing on the unmet medical needs of patients with rare disorders and their families

More

Our Company

Progressing our mission to improve the lives of patients battling certain rare and near-rare diseases

More

Our Pipeline

Pioneering cannabinoid treatments for neuropsychiatric conditions

More

Latest News

05.24

Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the American Society of Clinical Psychopharmacology Annual Meeting

Read More
05.17

Zynerba Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

Read More
05.16

Zynerba Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights

Read More
05.11

Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome (FXS) at the International Society for Autism Research Annual Meeting

Read More

This site uses cookies to give you a better browsing experience. By continuing to use this website, you accept our use of these cookies. For more information, see our Privacy Notice.